Renal malignant tumor with the loss of INI1 expression and WT1 positive in a 3-year-old boy: a case report.

Transl Androl Urol

Department of Pathology, the Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.

Published: October 2020


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Wilms' tumor is the most common primary renal malignancy in children (80%) and the less common tumors include renal cell carcinoma, rhabdoid tumor, clear cell sarcoma, cellular congenital mesoblastic nephroma and medullary carcinoma, all of which originate from renal parenchyma. The tumors originating from renal pelvis are rare. The immunohistochemistry (IHC) showed INI1 deletion with the WT1 positive which has not been reported as we know. A 3-year-old boy was admitted to hospital for vomiting. An ultrasonography examination revealed a mass in the right kidney, medium echo, as well as hydronephrosis with collecting system separation of 3.5 cm. The computed tomography and the magnetic resonance (MR) radical showed that the tumor occupied the right renal pelvis and extended into the ureter. A radical nephroureterectomy was accomplished through a transabdominal approach. The pathologic diagnosis was malignant renal tumor with INI1 deficiency which was atypical in morphology and immunophenotype, but according to immunophenotype renal rhabdomyoid tumor could not be excluded. The patient was treated with carboplatin, etoposide and cyclophosphamide chemotherapy for 6 months. Follow-up studies of the patient showed no indication of recurrence or metastasis 22 months after nephrectomy. The novel findings may expand the spectrum of pediatric renal tumors to include the special malignancy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7658110PMC
http://dx.doi.org/10.21037/tau-20-834DOI Listing

Publication Analysis

Top Keywords

renal
9
wt1 positive
8
3-year-old boy
8
tumors include
8
renal pelvis
8
tumor
6
renal malignant
4
malignant tumor
4
tumor loss
4
loss ini1
4

Similar Publications

Super Responder of 177Lu-PSMA-617 PSMA Therapy in Patient With End-Stage Renal Disease on Hemodialysis.

Clin Nucl Med

September 2025

Department of Radiology and Nuclear Medicine, Comprehensive Cancer Care and Research Center (SQCCCRC), University Medical City, Muscat, Oman.

PSMA-targeted radioligand therapies with 177Lu-PSMA-617 have shown promising response rates with favorable toxicity in patients with metastasized castration-resistant prostate cancer. We report a case of a 72-year-old man with metastatic castration-resistant prostate cancer having comorbidities of DM, HTN, and end-stage renal disease (ESRD) on regular hemodialysis. The patient received 2 doses of 7.

View Article and Find Full Text PDF

Background: Chronic kidney disease (CKD) is associated with a higher prevalence of valvular diseases and increased mortality from cardiovascular causes. Factors that influence the genesis of cardiac valve calcification (CVC) in these patients are not well-defined.

Objective: To determine the risk factors for valvular calcification in patients with CKD.

View Article and Find Full Text PDF

Aims: Several diuretic strategies, including furosemide iv boluses (FB) or continuous infusion (FC), are used in acute heart failure (AHF).

Methods And Results: We systematically searched phase 3 randomized clinical trials (RCTs) evaluating diuretic regimens in admitted AHF patients within 48 hours and irrespective of clinical stabilization. We calculated the odds ratio (OR) of FC or FB plus another diuretic (sequential nephron blockade, SNB) compared to FB alone on 24-hour weight loss (WL) and worsening renal function (WRF), with a random-effects model with inverse variance weighting.

View Article and Find Full Text PDF

IFN-β, a type I interferon, has been used as a first-line therapy for patients with multiple sclerosis (MS) for more than 30 years; however, the cellular and molecular basis of its therapeutic efficacy remains unclear. Here, we first used experimental autoimmune encephalomyelitis (EAE), a mouse model for MS, to show that the therapeutic effects of IFN-β were associated with a down-regulation of microRNA-21 (miR-21) and pathogenic T17 (pT17) cells. In vitro experiments demonstrated that genetic knockout of miR-21 directly inhibited pathogenic T17 cell differentiation.

View Article and Find Full Text PDF